É. Pap

发表

[Pharmacokinetic analysis of high-dose methotrexate treatments in children with hematologic malignancies].

G. Kovács, M. Csóka, K. Csordás, 2011, Orvosi Hetilap.

Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase

V. Adleff, J. Kralovánszky, B. Budai, 2010, Cancer Chemotherapy and Pharmacology.

[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].

E. Hitre, V. Adleff, J. Kralovánszky, 2007, Magyar onkologia.

IDENTIFICATION AND CLINICAL RELEVANCE OF PHENOTYPE MODIFYING GENETIC FACTORS IN MONOGENIC DISEASES

N. Nagy, É. Pap, 2020 .

Identification of putative phenotype‐modifying genetic factors associated with phenotypic diversity in Brooke‐Spiegler syndrome

N. Nagy, M. Széll, É. Pap, 2019, Experimental dermatology.

Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab

E. Hitre, I. Láng, V. Adleff, 2012, Pharmacogenetics and genomics.

Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts.

J. Kralovánszky, B. Budai, A. Zalatnai, 2009, Anticancer research.

Characterisation of bioenergetic pathways and related regulators by multiple assays in human tumour cells

I. Kovalszky, K. Vékey, J. Kralovánszky, 2016, Cancer Cell International.

Enhancement of 5-Fluorouracil Efficacy on High COX-2 Expressing HCA-7 Cells by Low Dose Indomethacin and NS-398 but not on Low COX-2 Expressing HT-29 Cells

V. Adleff, J. Kralovánszky, Andrea Réti, 2009, Pathology & Oncology Research.

High-performance liquid chromatographic determination of busulfan in plasma

J. Kralovánszky, V. Erdélyi-Tóth, É. Pap, 2000 .

High-Performance liquid chromatographic determination of dibromomannitol in plasma

J. Kralovánszky, V. Erdélyi-Tóth, É. Pap, 1998 .

Pharmacokinetic studies on Elobromol in children with brain tumors

D. Schuler, É. Pap, C. Csáki, 1994, Anti-cancer drugs.

Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.

V. Adleff, J. Kralovánszky, Judit Müller, 2008, Anticancer research.

SHMT1 1420 and MTHFR 677 variants are associated with rectal but not colon cancer

P. Rudnai, E. Hitre, V. Adleff, 2010, BMC Cancer.

Pharmacokinetics of panomifene in healthy volunteers at phase I/a study

I. Klebovich, S. Drabant, É. Pap, 1997, Anti-cancer drugs.